Clinical trial • Phase III • Neurology
Adipose tissue-derived stem/stromal cells for Alzheimer's disease
Phase III trial of Adipose tissue-derived stem/stromal cells for Alzheimer's disease. 9 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Alzheimer's disease
- Trial Stage
- Phase III
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 12-12-2024
- First CTIS Authorization Date
- 07-05-2025
Trial design
Phase III trial across 1 site in France.
- Target Sample Size
- 9
Recruitment
- Planned Sample Size
- 9
- Recruitment Window Months
- 36
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 9
France
- Earliest CTIS Part Ii Submission Date
- 31-03-2025
- Latest Decision Or Authorization Date
- 09-02-2026
- Processing Time Days
- 315
- Number Of Sites
- 1
- Number Of Participants
- 9
Sites
- Site Name
- Centre Hospitalier Universitaire De Toulouse (9 Place Lange)
- Department Name
- Geriatry
- Principal Investigator Name
- Julien DELRIEU
- Principal Investigator Email
- delrieu.j@chu-toulouse.fr
- Contact Person Name
- Julien DELRIEU
- Contact Person Email
- delrieu.j@chu-toulouse.fr
Sponsor
Primary sponsor
- Full Name
- Centre Hospitalier Universitaire De Toulouse
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- France
Investigational products
- Investigational Product Name
- Allogeneic adipose tissue derived-stem cells
- Active Substance
- Adipose tissue-derived stem/stromal cells
- Modality
- Cell therapy
- Routes Of Administration
- Intravenous
- Route
- Intravenous
Related trials
Other published trials that may interest you.